Observational Connectomics in Adults Undergoing Resection of WHO II-IV Glioma
Key facts
- Where
- New York, United StatesSee the site
Where in United States
- Lenox Hill Brain Tumor CenterNew York, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Northwell Health
- Trial code
- NCT07927595
- Record updated
- 10 November 2026
- Original description
This observational study will create a large scale database (registry) of glioma patients' data across multiple participating institutions (hospitals) to study a range of clinical research questions.Read full original descriptionShow less
A Prospective, Longitudinal, Multi-Institutional, Observational Study to Correlate Quantitative Changes of the Human Structural and Functional Connectome in Adults Undergoing Neurosurgical Resection of WHO II-IV Glioma
This observational study will create a large scale database (registry) of glioma patients' data across multiple participating institutions (hospitals) to study a range of clinical research questions.
Inclusion: Age > 18 years; Newly diagnosed patients (by MRI) suspected of having a brain tumor (WHO II,III, or IV) who will undergo surgery with histological confirmation or patients undergoing surgery for recurrent brain tumor (WHO grades II, III, IV) whose histology confirms glioma and/or treatment effect; Diffuse astrocytomas, multifocal gliomas, oligodendrogliomas, midline and brainstem gliomas are included; Previously treated (progressive, recurrent) gliomas are included. Thus, prior surgery, radiation therapy, anti-angiogenic therapy, electrical field therapy are not exclusions; Patient must be able to give informed consent. S/he must be able to read and understand English or there must be a qualified interpreter; Must be able to undergo sequential MRI in a facility that can perform 30-directional MRI for connectomic analyses.
Exclusion: Tissue samples obtained at surgery are insufficient/ or non-diagnostic for glioma; Medications. There are no restrictions on medications. Patients will receive best standard of care; Expected survival < 90 days due to primary disease or medical co-morbidities. (e.g. sepsis, pneumonia, organ failure); Inability to have a MRI due to cardiac pacemaker, implants, claustrophobia, allergy to gadolinium,; Pregnancy. Because of potential risk of serial MRI to fetus, women of child-bearing age will need a pregnancy test and agree to contraceptive practices during the course of the study; Age < 17; Juvenile pilocytic glioma (WHO I); Histology that is non-glioma, e.g., brain metastases, craniopharyngioma, ependymoma, medulloblastoma, meningioma, lymphoma, tumefactive (demyelinative) plaque, abscess, germinoma, arachnoid cyst, epidermoid, PXA, DNET, ganglioglioma, central neurocytoma,; Inability to give informed consent; Vulnerable population; Clinical Trials. Patients may also be enrolled in a clinical trial as a clinical trial is always recommended for patients with a glioma per NCCN guidelines; KPS < 40.